Posted:
11/19/2024, 6:23:32 AM
Location(s):
Boston, Massachusetts, United States ⋅ Massachusetts, United States
Experience Level(s):
Expert or higher ⋅ Senior
Field(s):
Finance & Banking
Building on our founders’ Nobel-prize winning discoveries in RNA interference, Atalanta Therapeutics is developing novel branched siRNA therapeutics to treat severe neurological diseases at the root cause. With two active partnerships with large biopharmaceutical companies plus a robust and growing internal pipeline, Atalanta is poised to make a difference in patients’ lives. Atalanta fosters a culture of integrity, respect, collaboration, opportunity, learning, and fun. We are located in Boston’s vibrant Seaport district near South Station.
POSITION SUMMARY:
Atalanta is seeking a highly motivated and hands-on Controller to join our Finance team. Reporting to the Chief Financial Officer, this individual will be responsible for overseeing financial reporting activities, compliance and regulatory requirements, as well as managing internal controls and audits. The Controller will have the demonstrated ability to work both independently as well as part of a cross-functional team to manage technical accounting processes that advance drug development efforts across the organization. The ideal candidate will be instrumental in implementing efficient accounting processes and best practices while operating with the highest standards of accuracy as we continue to grow in a highly regulated industry.
RESPONSIBILITIES:
QUALIFICATIONS:
Atalanta is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person’s race, color, sex, gender identity or expression, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, sexual orientation, marital status, or any characteristic protected under applicable law.
Website: https://www.atalantatx.com/
Headquarter Location: Boston, Massachusetts, United States
Employee Count: 11-50
Year Founded: 2018
IPO Status: Private
Last Funding Type: Series A
Industries: Biotechnology ⋅ Life Science